Efficiency of one of the most widely spread rheumatic disease – rheumatoid arthritis (RA) treatment has increased greatly in the last decade because of development and introduction into clinical practice of new medications, which can prevent inevitable progressing of joints destruction and joint dysfunction in patients with RA. Studies of RA pathogenesis allowed to make a conclusion about necessity in active early treatment, application of basic anti-inflammatory therapy (BAIT), because it can help to modify clinical course of the disease more efficiently and also it ensures positive prognosis for functional condition of affected joints. Appearance of new group of preparations – biological agents (antycytoktine therapy) and their application in combination with traditional means of BAIT allow to achieve a significant success in treatment of RA patients. At the same time it was found that duration of “therapeutic period” – a period of time since the moment of definite RA diagnosing till the moment when active therapy poorly affects joints destruction – is quite short – a year approximately, and the best results are achieved in the beginning of a therapy, within first three months since the incursion of the disease.